Qiagen N.V.

  • WKN: A2DKCH
  • ISIN: NL0012169213
  • Land: The Netherlands

Nachricht vom 03.07.2018 | 11:30

QIAGEN N.V.: Release of a capital market information

QIAGEN N.V. / Share buyback

03.07.2018 / 11:30
Dissemination of a Post-admission Duties announcement transmitted by DGAP -
a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase - Interim Reporting With disclosure dated May 15, 2018, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the immediate beginning of a first tranche of up to USD 50 million under the share repurchase program originally announced on January 31, 2018. The number of shares which have been bought back on the electronic trading platform of the Frankfurt Stock Exchange (XETRA) within the framework of such tranche of the share repurchase program in the time period from June 25, 2018 until and including June 29, 2018 amounts to 245,222 shares. Shares were bought back as follows:

Date          Number of Shares    Average Price      Purchased Volume (EUR)
              acquired            (EUR)
25-June-2018  29,664              31.1478            923,968.34
26-June-2018  29,935              30.7666            920,998.17
27-June-2018  80,110              30.6700            2,456,973.70
28-June-2018  80,475              30.5311            2,456,990.27
29-June-2018  25,038              31.1926            781,000.32
Total         245,222             30.7474            7,539,930.80


The underlying individual trades are published on the website of QIAGEN N.V. (http://corporate.qiagen.com/investor-relations/share-information/ share-buyback). The total number of shares which have already been bought back within the framework of such tranche of the share repurchase program from May 15, 2018 until and including June 29, 2018 amounts to 818,636 shares. The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V. Venlo, 03 July 2018 Managing Board ### Contacts: QIAGEN Investor Relations John Gilardi +49 2103 29 11711 e-mail:ir@qiagen.com Public Relations Dr. Thomas Theuringer +49 2103 29 11826 e-mail:pr@qiagen.com
03.07.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language: English Company: QIAGEN N.V. Hulsterweg 82 5912 PL Venlo Netherlands Internet: www.qiagen.com End of News DGAP News Service

GBC-Fokusbox

UniDevice AG: Rekord-Ergebnis in 2018

Nach starkem Schlussspurt hat die UniDevice AG in 2018 Umsatz und Ergebnis deutlich gesteigert. Der B2B-Broker für hochpreisige Smartphones sollte auch künftig eine hohe Nachfrage verzeichnen und von der Ausnutzung unterschiedlicher Preisniveaus in den verschiedenen Ländern profitieren. Der Umsatz soll 2019 auf mindestens 380 Mio. € und in 2020 auf mindestens 410 Mio. € ansteigen, nachdem 2018 317 Mio. € erreicht wurden. Bei einem ermittelten Kursziel in Höhe von 2,35 € lautet das Rating KAUFEN.

News im Fokus

Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2018

21. Februar 2019, 11:51

Aktueller Webcast

Ströer SE & Co. KGaA

Vorläufige Geschäftszahlen 2018

26. Februar 2019

Aktuelle Research-Studie

Sanochemia Pharmazeutika AG

Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy

21. Februar 2019